TWI688571B - 化合物（四） - Google Patents
化合物（四） Download PDFInfo
- Publication number
- TWI688571B TWI688571B TW104138186A TW104138186A TWI688571B TW I688571 B TWI688571 B TW I688571B TW 104138186 A TW104138186 A TW 104138186A TW 104138186 A TW104138186 A TW 104138186A TW I688571 B TWI688571 B TW I688571B
- Authority
- TW
- Taiwan
- Prior art keywords
- general formula
- alkyl
- compound
- group
- halogen
- Prior art date
Links
- 0 C[C@](**)[C@@]([C@@](*)CC1C23)[C@@]1(C)C(*)CC2[C@@](C)(CCC(C1)=O)[C@@]1CC3=O Chemical compound C[C@](**)[C@@]([C@@](*)CC1C23)[C@@]1(C)C(*)CC2[C@@](C)(CCC(C1)=O)[C@@]1CC3=O 0.000 description 5
- LXBMCVWCVCPPQN-CAUNPKPKSA-N CCC[C@@](C)(CC)C(CC1)C([C@@H](C)O)C(CC2)[C@@]1(C)C2[C@H](C)CCC(OCC)=O Chemical compound CCC[C@@](C)(CC)C(CC1)C([C@@H](C)O)C(CC2)[C@@]1(C)C2[C@H](C)CCC(OCC)=O LXBMCVWCVCPPQN-CAUNPKPKSA-N 0.000 description 1
- WBZBIQFRIIBHBI-QWYIYZBFSA-N CCOC(/C=C/[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O)=O Chemical compound CCOC(/C=C/[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O)=O WBZBIQFRIIBHBI-QWYIYZBFSA-N 0.000 description 1
- MRTBVEZPPZIQIP-SARUPGJCSA-N CCOC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O)=O Chemical compound CCOC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O)=O MRTBVEZPPZIQIP-SARUPGJCSA-N 0.000 description 1
- ALRMAFWSBULXAH-UDJDKGKESA-N CC[C@@H]([C@@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(OCC)=O)[C@H]2O Chemical compound CC[C@@H]([C@@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(OCC)=O)[C@H]2O ALRMAFWSBULXAH-UDJDKGKESA-N 0.000 description 1
- ALRMAFWSBULXAH-VPMYRDHBSA-N CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(OCC)=O)[C@H]2O Chemical compound CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(OCC)=O)[C@H]2O ALRMAFWSBULXAH-VPMYRDHBSA-N 0.000 description 1
- ALRMAFWSBULXAH-LVOIAGQNSA-N CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OCC)=O)[C@H]2O Chemical compound CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OCC)=O)[C@H]2O ALRMAFWSBULXAH-LVOIAGQNSA-N 0.000 description 1
- IIBUJDFABBCWNC-QUGSHNCDSA-N CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)/C=C/C(OCC)=O)C2[C@@]1(C)CC2)O)C1=CC2=O Chemical compound CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)/C=C/C(OCC)=O)C2[C@@]1(C)CC2)O)C1=CC2=O IIBUJDFABBCWNC-QUGSHNCDSA-N 0.000 description 1
- SMEROWZSTRWXGI-UBYLEJEVSA-N C[C@H](CCC(O)=O)[C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)[C@H]1C[C@@H]2O Chemical compound C[C@H](CCC(O)=O)[C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)[C@H]1C[C@@H]2O SMEROWZSTRWXGI-UBYLEJEVSA-N 0.000 description 1
- XHQVLSIVZIPGLE-ORNFQILJSA-N C[C@H](CCC(OC)=O)[C@@H](CCC1C(CC2)C(C3)[C@@](C)(CC4)[C@H]2C[C@@H]4OC(C)=O)[C@@]1(C)C3=O Chemical compound C[C@H](CCC(OC)=O)[C@@H](CCC1C(CC2)C(C3)[C@@](C)(CC4)[C@H]2C[C@@H]4OC(C)=O)[C@@]1(C)C3=O XHQVLSIVZIPGLE-ORNFQILJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1420594.2A GB201420594D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GB1420593.4 | 2014-11-19 | ||
| GB1420594.2 | 2014-11-19 | ||
| GBGB1420593.4A GB201420593D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GBGB1505675.7A GB201505675D0 (en) | 2015-04-01 | 2015-04-01 | Compounds |
| GB1505675.7 | 2015-04-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201632539A TW201632539A (zh) | 2016-09-16 |
| TWI688571B true TWI688571B (zh) | 2020-03-21 |
Family
ID=54704022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104138186A TWI688571B (zh) | 2014-11-19 | 2015-11-19 | 化合物（四） |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170327531A1 (https=) |
| EP (1) | EP3221334B1 (https=) |
| JP (1) | JP6698085B2 (https=) |
| KR (1) | KR102527821B1 (https=) |
| CN (1) | CN107207558B (https=) |
| CA (1) | CA2968310A1 (https=) |
| EA (1) | EA033603B1 (https=) |
| MX (1) | MX381239B (https=) |
| TW (1) | TWI688571B (https=) |
| WO (1) | WO2016079520A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207559B (zh) | 2014-11-19 | 2019-10-25 | Nzp英国有限公司 | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| EA033445B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| JP2018538331A (ja) * | 2015-12-22 | 2018-12-27 | インターセプト ファーマシューティカルズ， インコーポレイテッド | オベチコール酸の多型結晶形態 |
| GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106046093A (zh) * | 2016-05-30 | 2016-10-26 | 华东师范大学 | 一种石胆酸的合成方法 |
| EP3431486A1 (en) | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN116178473B (zh) * | 2018-12-10 | 2025-03-04 | 江西科睿药业有限公司 | 一种奥贝胆酸的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200736271A (en) * | 2006-01-12 | 2007-10-01 | Mitsubishi Chem Corp | Process for production of steroids |
| CN101203526A (zh) * | 2005-05-19 | 2008-06-18 | 伊莱吉尔瑞公司 | 制备3α(β)-7α(β)-二羟基-6α(β)-烷基-5β-胆烷酸的方法 |
| CN102282157A (zh) * | 2008-11-19 | 2011-12-14 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| ES2248581T3 (es) | 2001-03-12 | 2006-03-16 | Intercept Pharmaceuticals, Inc. | Esteroides como agonistas de fxr. |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| KR101555716B1 (ko) | 2007-01-19 | 2015-09-25 | 인터셉트 파마슈티컬즈, 인크. | Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법 |
| WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| SI3336097T1 (sl) | 2012-06-19 | 2021-07-30 | Intercept Pharmaceuticals, Inc. | Priprava nekristalinične oblike obetiholne kisline |
| SG11201503247UA (en) | 2012-10-26 | 2015-06-29 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| AU2013352288B2 (en) * | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| TN2015000497A1 (en) | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| SG11201509371XA (en) | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific markers for diagnosing irritable bowel syndrome |
| US10166246B2 (en) * | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| SMT202000070T1 (it) | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1 |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| CN107207559B (zh) | 2014-11-19 | 2019-10-25 | Nzp英国有限公司 | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 |
| EA033445B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| JP6861703B2 (ja) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｔｇｒ５修飾物質およびその使用方法 |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
-
2015
- 2015-11-19 KR KR1020177016858A patent/KR102527821B1/ko active Active
- 2015-11-19 US US15/528,341 patent/US20170327531A1/en not_active Abandoned
- 2015-11-19 WO PCT/GB2015/053519 patent/WO2016079520A1/en not_active Ceased
- 2015-11-19 EP EP15800912.6A patent/EP3221334B1/en active Active
- 2015-11-19 EA EA201790885A patent/EA033603B1/ru not_active IP Right Cessation
- 2015-11-19 MX MX2017006567A patent/MX381239B/es unknown
- 2015-11-19 TW TW104138186A patent/TWI688571B/zh not_active IP Right Cessation
- 2015-11-19 CA CA2968310A patent/CA2968310A1/en not_active Abandoned
- 2015-11-19 CN CN201580062901.6A patent/CN107207558B/zh active Active
- 2015-11-19 JP JP2017527810A patent/JP6698085B2/ja active Active
-
2018
- 2018-10-17 US US16/163,259 patent/US10597423B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101203526A (zh) * | 2005-05-19 | 2008-06-18 | 伊莱吉尔瑞公司 | 制备3α(β)-7α(β)-二羟基-6α(β)-烷基-5β-胆烷酸的方法 |
| TW200736271A (en) * | 2006-01-12 | 2007-10-01 | Mitsubishi Chem Corp | Process for production of steroids |
| CN102282157A (zh) * | 2008-11-19 | 2011-12-14 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170327531A1 (en) | 2017-11-16 |
| TW201632539A (zh) | 2016-09-16 |
| US10597423B2 (en) | 2020-03-24 |
| EP3221334A1 (en) | 2017-09-27 |
| EA033603B1 (ru) | 2019-11-08 |
| JP6698085B2 (ja) | 2020-05-27 |
| CA2968310A1 (en) | 2016-05-26 |
| KR102527821B1 (ko) | 2023-05-02 |
| HK1244286A1 (en) | 2018-08-03 |
| MX2017006567A (es) | 2018-01-26 |
| MX381239B (es) | 2025-03-12 |
| EA201790885A1 (ru) | 2017-11-30 |
| US20190077827A1 (en) | 2019-03-14 |
| JP2017534669A (ja) | 2017-11-24 |
| EP3221334B1 (en) | 2020-02-19 |
| KR20170099896A (ko) | 2017-09-01 |
| CN107207558A (zh) | 2017-09-26 |
| CN107207558B (zh) | 2019-10-29 |
| WO2016079520A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI688571B (zh) | 化合物（四） | |
| TWI690536B (zh) | 化合物（一） | |
| TWI686401B (zh) | 化合物（三） | |
| TWI686400B (zh) | 化合物（二） | |
| HK1244285A1 (en) | 5.beta -6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| HK1244286B (en) | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| HK1244287B (en) | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| HK1246801B (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |